KALA BIO (KALA) Competitors $6.55 -0.20 (-2.96%) Closing price 03/14/2025 03:59 PM EasternExtended Trading$6.50 -0.05 (-0.76%) As of 03/14/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends KALA vs. PLX, GNFT, CTNM, CCCC, CRGX, LRMR, NBTX, NLTX, PBYI, and CDTXShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Protalix BioTherapeutics (PLX), Genfit (GNFT), Contineum Therapeutics (CTNM), C4 Therapeutics (CCCC), CARGO Therapeutics (CRGX), Larimar Therapeutics (LRMR), Nanobiotix (NBTX), Neoleukin Therapeutics (NLTX), Puma Biotechnology (PBYI), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Protalix BioTherapeutics Genfit Contineum Therapeutics C4 Therapeutics CARGO Therapeutics Larimar Therapeutics Nanobiotix Neoleukin Therapeutics Puma Biotechnology Cidara Therapeutics Protalix BioTherapeutics (NYSE:PLX) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations. Is PLX or KALA more profitable? KALA BIO has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% KALA BIO N/A -448.61%-69.37% Does the media favor PLX or KALA? In the previous week, Protalix BioTherapeutics had 1 more articles in the media than KALA BIO. MarketBeat recorded 2 mentions for Protalix BioTherapeutics and 1 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Protalix BioTherapeutics' score of -0.06 indicating that KALA BIO is being referred to more favorably in the news media. Company Overall Sentiment Protalix BioTherapeutics Neutral KALA BIO Very Positive Does the MarketBeat Community believe in PLX or KALA? KALA BIO received 290 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 78.57% of users gave Protalix BioTherapeutics an outperform vote while only 66.89% of users gave KALA BIO an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes1178.57% Underperform Votes321.43% KALA BIOOutperform Votes30166.89% Underperform Votes14933.11% Do analysts recommend PLX or KALA? Protalix BioTherapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 569.64%. KALA BIO has a consensus target price of $15.00, suggesting a potential upside of 129.01%. Given Protalix BioTherapeutics' higher probable upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, PLX or KALA? Protalix BioTherapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.19, suggesting that its stock price is 319% less volatile than the S&P 500. Which has stronger valuation & earnings, PLX or KALA? Protalix BioTherapeutics has higher revenue and earnings than KALA BIO. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$45.67M3.61$8.31M-$0.13-17.23KALA BIO$3.89M10.26-$42.20M-$12.47-0.53 Do insiders and institutionals hold more shares of PLX or KALA? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 6.3% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 8.3% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryProtalix BioTherapeutics beats KALA BIO on 9 of the 17 factors compared between the two stocks. Remove Ads Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.90M$7.03B$5.67B$8.13BDividend YieldN/A2.75%4.40%4.08%P/E Ratio-0.536.2623.8119.04Price / Sales10.26232.36394.8188.14Price / CashN/A65.6738.0534.64Price / Book2.356.596.834.29Net Income-$42.20M$142.18M$3.19B$247.40M7 Day Performance-7.09%-1.29%6.56%-0.85%1 Month Performance-21.84%-8.97%-0.36%-9.36%1 Year Performance-13.01%-6.25%11.95%4.03% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO4.2788 of 5 stars$6.55-3.0%$15.00+129.0%-14.2%$39.90M$3.89M-0.5330PLXProtalix BioTherapeutics2.1042 of 5 stars$2.31-0.9%$15.00+549.4%+63.5%$170.10M$45.67M-17.77200Analyst UpgradeNews CoverageHigh Trading VolumeGNFTGenfit1.9617 of 5 stars$3.40-2.0%$13.00+282.4%+0.7%$169.99M$76.06M0.00120Positive NewsGap UpHigh Trading VolumeCTNMContineum Therapeutics2.6213 of 5 stars$6.59-6.4%$29.25+343.9%N/A$169.88M$50M0.0031Analyst ForecastNews CoveragePositive NewsCCCCC4 Therapeutics2.1204 of 5 stars$2.40-11.4%$12.50+420.8%-78.7%$169.41M$33.67M-1.41150Gap DownCRGXCARGO Therapeutics3.1493 of 5 stars$3.68-2.1%$15.00+307.6%-85.0%$169.38MN/A-0.86116Upcoming EarningsAnalyst RevisionLRMRLarimar Therapeutics2.3805 of 5 stars$2.65-12.5%$20.13+659.4%-70.2%$169.09MN/A-2.3030NBTXNanobiotix1.8862 of 5 stars$3.57+1.7%$12.00+236.1%-48.6%$168.27M$36.22M0.00100Short Interest ↑NLTXNeoleukin TherapeuticsN/A$17.69+3.5%N/A-51.4%$166.25MN/A-5.6990News CoveragePBYIPuma Biotechnology3.8447 of 5 stars$3.35-6.4%$7.00+109.0%-36.4%$164.45M$243.57M6.98200CDTXCidara Therapeutics4.3791 of 5 stars$23.05-7.4%$32.20+39.7%+72.0%$162.43M$44.65M-0.9090Analyst ForecastShort Interest ↑Analyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies Protalix BioTherapeutics Competitors Genfit Competitors Contineum Therapeutics Competitors C4 Therapeutics Competitors CARGO Therapeutics Competitors Larimar Therapeutics Competitors Nanobiotix Competitors Neoleukin Therapeutics Competitors Puma Biotechnology Competitors Cidara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
